R R Forastiero

Summary

Affiliation: Favaloro University
Country: Argentina

Publications

  1. ncbi A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis
    R Forastiero
    Division of Hematology, Thrombosis and Hemostasis, Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation, Favaloro University, Buenos Aires, Argentina
    J Thromb Haemost 3:1231-8. 2005
  2. ncbi Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies
    R R Forastiero
    Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Lupus 14:129-36. 2005
  3. ncbi Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor
    R R Forastiero
    Division of Haematology, Thrombosis and Haemostasis, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    J Thromb Haemost 1:1764-70. 2003
  4. ncbi High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome
    R R Forastiero
    Division of Haematology, Thrombosis and Haemostasis, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    J Thromb Haemost 1:718-24. 2003
  5. ncbi High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity
    G F de Larrañaga
    Section of Biochemistry, Thrombosis and Haemostasis, Hospital of Infectious Diseases FJ Muñiz, Buenos Aires, Argentina
    Lupus 9:594-600. 2000
  6. ncbi Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies
    M E Martinuzzo
    Institute of Cardiology and Cardiovascular Surgery, Division of Haematology, the Favaloro University School of Medicine, Favaloro Foundation, , Buenos Aires, Argentina
    Br J Haematol 114:845-51. 2001
  7. ncbi Markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with antiphospholipid antibodies
    M E Martinuzzo
    Division of Haematology, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Clin Exp Rheumatol 20:477-83. 2002
  8. ncbi Central retinal vein occlusion and thrombophilia risk factors
    Y P Adamczuk
    Department of Haematology, Thrombosis and Haemostasis, Favaloro University, Buenos Aires, Argentina
    Blood Coagul Fibrinolysis 13:623-6. 2002
  9. ncbi Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome
    G F de Larrañaga
    Hospital of Infectious Diseases F J Muñiz, Buenos Aires, Argentina
    Thromb Res 96:19-25. 1999
  10. ncbi Link between anti-CD36 antibodies and thrombosis in the antiphospholipid syndrome
    Y Pelegri
    Division of Haematology, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Clin Exp Rheumatol 21:221-4. 2003

Collaborators

Detail Information

Publications16

  1. ncbi A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis
    R Forastiero
    Division of Hematology, Thrombosis and Hemostasis, Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation, Favaloro University, Buenos Aires, Argentina
    J Thromb Haemost 3:1231-8. 2005
    ..4% per patient-year). In conclusion, the presence of IgG anti-beta2GPI and anti-PT in patients with LA and/or aCL and mainly in those with LA predicts a higher risk of thromboembolic events...
  2. ncbi Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies
    R R Forastiero
    Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Lupus 14:129-36. 2005
    ..The different cytokine profiles as well as differences in circulating levels of TF might contribute to the high thrombotic risk found in patients with autoimmune aPL but not in leprosy related aPL patients...
  3. ncbi Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor
    R R Forastiero
    Division of Haematology, Thrombosis and Haemostasis, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    J Thromb Haemost 1:1764-70. 2003
    ..Taken together, these data suggest that the PZ/ZPI system is commonly impaired in aPL patients thus probably increasing the thrombotic risk...
  4. ncbi High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome
    R R Forastiero
    Division of Haematology, Thrombosis and Haemostasis, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    J Thromb Haemost 1:718-24. 2003
    ..Thus, aPL with high titer anti-TFPI limit TFPI action and are associated with the APS...
  5. ncbi High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity
    G F de Larrañaga
    Section of Biochemistry, Thrombosis and Haemostasis, Hospital of Infectious Diseases FJ Muñiz, Buenos Aires, Argentina
    Lupus 9:594-600. 2000
    ..In summary, leprosy-related aPL resemble those found in patients with APS but the immunoglobulin isotype is different, with IgM much more prevalent in leprosy patients...
  6. ncbi Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies
    M E Martinuzzo
    Institute of Cardiology and Cardiovascular Surgery, Division of Haematology, the Favaloro University School of Medicine, Favaloro Foundation, , Buenos Aires, Argentina
    Br J Haematol 114:845-51. 2001
    ..Platelet activation, lipid peroxidation and blood coagulation activation seem to be important in the pathophysiology of antiphospholipid syndrome...
  7. ncbi Markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with antiphospholipid antibodies
    M E Martinuzzo
    Division of Haematology, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Clin Exp Rheumatol 20:477-83. 2002
    ..CONCLUSIONS: We demonstrated that although patients with leprosy present a high prevalence of aPL, and platelet and endothelial cell activation in vivo to the same extent than patients with APS, they do not show a procoagulant state...
  8. ncbi Central retinal vein occlusion and thrombophilia risk factors
    Y P Adamczuk
    Department of Haematology, Thrombosis and Haemostasis, Favaloro University, Buenos Aires, Argentina
    Blood Coagul Fibrinolysis 13:623-6. 2002
    ..5%, P < 0.001 and 2.1%, P < 0.01, respectively). Both hyperhomocysteinaemia and antiphospholipid antibodies seem to be associated with CRVO. A search for acquired thrombophilia is advisable in patients with CRVO...
  9. ncbi Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome
    G F de Larrañaga
    Hospital of Infectious Diseases F J Muñiz, Buenos Aires, Argentina
    Thromb Res 96:19-25. 1999
    ..Autoimmune antiphospholipid antibodies in HIV without clinical features of antiphospholipid syndrome might be a reflex of the immunological chaos and/or the constant antigenic virus stimulus...
  10. ncbi Link between anti-CD36 antibodies and thrombosis in the antiphospholipid syndrome
    Y Pelegri
    Division of Haematology, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Clin Exp Rheumatol 21:221-4. 2003
    ..8% vs 15.8%). CONCLUSION: The presence of anti-CD36 is highly prevalent in patients with autoimmune aPL with a trend to being more frequent in patients with recurrent episodes of thrombosis...
  11. ncbi Thrombophilic factors in chronic thromboembolic pulmonary hypertension
    C C Colorio
    Department of Hematology, Institute of Cardiology and Cardiovascular Surgery, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    Blood Coagul Fibrinolysis 12:427-32. 2001
    ..We recommend a thorough screening for thrombophilia in all patients with diagnosis of CTE-PH...
  12. ncbi New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests
    M E Martinuzzo
    Division of Hematology, Thrombosis, and Haemostasis, University Hospital, Favaloro Foundation, Buenos Aires, Argentina
    Int J Lab Hematol 34:208-13. 2012
    ..Conclusion:  The combination of mixing and confirmatory tests interpreted according to the new guidelines can clearly differentiate LA from other coagulopathies...
  13. ncbi Which are the best biological markers of the antiphospholipid syndrome?
    L O Carreras
    Department of Haematology, Thrombosis and Haemostasis, Favaloro University, Favaloro Foundation, Buenos Aires, Argentina
    J Autoimmun 15:163-72. 2000
    ....
  14. ncbi Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism
    M L Varela
    Department of Haematology, Thrombosis and Haemostasis, Favaloro University, Buenos Aires, Argentina
    Thromb Res 104:317-24. 2001
    ..92, P<.0001). We conclude that FVL and the PT-20210A are risk factors for VT as well as Hcy levels, but the MTHFR and PAI-1 polymorphisms do not appear to be associated with VT in our country...
  15. ncbi Catastrophic antiphospholipid syndrome and Kikuchi-Fujimoto disease: the first case reported
    G F de Larrañaga
    Hemostasis and Thrombosis Laboratory, Muñiz Hospital, Buenos Aires, Argentina
    Lupus 14:967-9. 2005
    ..Cytomegalovirus could be involved in the development of both CAPS and KFD. Because of the severity of the case, we believe that XIGRIS noticeable improved the altered coagulation profile associated with CAPS...
  16. ncbi Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies
    R R Forastiero
    J Thromb Haemost 1:2250-1. 2003